淋巴样增强因子-1在胰腺导管腺癌中的表达及对预后的影响

doi:10.3760/cma.j.cn371439-20201111-00119

摘要/Abstract

摘要：

目的研究Wnt信号通路中淋巴样增强因子-1(LEF-1)在胰腺导管腺癌(PDAC)中的表达及其意义。方法采用荧光定量PCR检测人PDAC细胞株PANC-1和正常胰腺导管上皮细胞株HPDE6中LEF-1 mRNA的相对表达情况;收集2012年6月至2013年12月新疆医科大学附属肿瘤医院肝胆胰外科保存的胰腺癌组织标本45例及其对应的癌旁组织标本45例,应用免疫组织化学法检测癌组织及癌旁组织中LEF-1的表达情况,分析LEF-1的表达与患者临床病理特征和预后的关系。结果荧光定量PCR示PANC-1细胞株中LEF-1 mRNA的相对表达量明显高于HPDE-6细胞株(2.895±0.485 vs. 1.006±0.126,t=3.056,P<0.001)。免疫组织化学结果显示,LEF-1在癌组织中高表达33例(73.3%),高于癌旁组织的12例(26.7%),差异有统计学意义(χ²=14.815,P<0.001);LEF-1的表达与术前糖类抗原(CA)19-9水平(P<0.001)、局部淋巴结转移(P=0.041)有关。生存分析示,PDAC患者整体中位总生存期(OS)为22.0个月,LEF-1高表达患者(n=33)中位OS为19.0个月,LEF-1低表达患者(n=12)中位OS为31.0个月,差异有统计学意义(χ²=5.554,P=0.018)。单因素Cox回归分析结果显示,与OS相关的因素有年龄(HR=1.962,95%CI为1.043~3.692,P=0.037)、LEF-1(HR=2.253,95%CI为1.097~4.630,P=0.027)和CA19-9(HR=2.667,95%CI为1.258~5.656,P=0.011)。多因素Cox回归分析示,CA19-9(HR=6.431,95%CI为1.078~38.382,P=0.041)、CA125(HR=0.151,95%CI为0.027~0.839,P=0.031)、原发肿瘤大小(HR=8.364,95%CI为1.925~36.335,P=0.005)、LEF-1(HR=2.281,95%CI为1.025~5.075,P=0.043)是影响PDAC患者预后的独立危险因素。结论 LEF-1在PDAC组织中表达上调,与术前CA19-9水平、局部淋巴结转移呈正相关,是PDAC患者预后的独立影响因素。

关键词: 淋巴样增强子结合因子1, Wnt信号通路, 胰腺肿瘤, 预后

Abstract:

Objective To investigate the expression of lymphoid enhancement factor-1 (LEF-1) in Wnt signaling pathway in pancreatic ductal adenocarcinoma (PDAC) and its significance. Methods The relative expressions of LEF-1 mRNA in human PDAC cell line PANC-1 and normal pancreatic ductal epithelial cell line HPDE6 were detected by fluorescence quantitative PCR. A total of 45 pancreatic cancer tissue specimens and their corresponding paracancerous tissue specimens were collected from the Department of Hepatobiliary and Pancreatic Surgery, Affiliated Tumor Hospital of Xinjiang Medical University from June 2012 to December 2013. The expressions of LEF-1 in the cancer tissues and paracancerous tissues were detected by immunohistochemistry, and the relationships between LEF-1 expression and clinicopathological characteristics and prognosis of patients were analyzed. Results Fluorescence quantitative PCR showed that the relative expression level of LEF-1 mRNA in PANC-1 cell line was significantly higher than that in HPDE-6 cell line (2.895±0.485 vs. 1.006±0.126, t=3.056, P<0.001). Immunohistochemical results showed that LEF-1 was highly expressed in 33 cases (73.3%) of cancer tissues, which was higher than that in 12 cases (26.7%) of adjacent tissues, and there was a statistically significant difference (χ²=14.815, P<0.001). LEF-1 expression was correlated with preoperative carbohydrate antigen (CA) 19-9 level (P<0.001) and local lymph node metastasis (P=0.041). Survival analysis showed that the median overall survival (OS) was 22.0 months in patients with PDAC, 19.0 months in patients with high LEF-1 expression (n=33), 31.0 months in patients with low LEF-1 expression (n=12), and there was a statistically significant difference (χ ²=5.554, P=0.018). Univariate Cox regression analysis showed that age (HR=1.962, 95%CI: 1.043-3.692, P=0.037), LEF-1 (HR=2.253, 95%CI: 1.097-4.630, P=0.027), and CA19-9 (HR=2.667, 95%CI: 1.258-5.656, P=0.011) were associated with OS. Multivariate Cox regression analysis showed that CA19-9 (HR=6.431, 95%CI: 1.078-38.382, P=0.041), CA125 (HR=0.151, 95%CI: 0.027-0.839, P=0.031), primary tumor size (HR=8.364, 95%CI: 1.925-36.335, P=0.005), LEF-1 (HR=2.281, 95%CI: 1.025-5.075, P=0.043) were independent risk factors affecting the prognosis of PDAC patients. Conclusion LEF-1 expression is up-regulated in PDAC tissues, which is positively correlated with preoperative CA19-9 level and local lymph node metastasis, and is an independent prognostic factor in patients with PDAC.

Key words: Lymphoid enhancer-binding factor 1, Wnt signaling pathway, Pancreatic neoplasms, Prognosis

李珂珂, 孔盼盼, 易超, 王喜艳, 晏冬. 淋巴样增强因子-1在胰腺导管腺癌中的表达及对预后的影响[J]. 国际肿瘤学杂志, 2021, 48(10): 608-613.

Li Keke, Kong Panpan, Yi Chao, Wang Xiyan, Yan Dong. Expression of lymphoid enhancer factor-1 in pancreatic ductal adenocarcinoma and its effect on prognosis[J]. Journal of International Oncology, 2021, 48(10): 608-613.

图/表 5

图1

表1

图2

表2

表3

参考文献 14

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019[J]. CA Cancer J Clin, 2019, 69(1):7-34. DOI: 10.3322/caac.21551. doi: 10.3322/caac.21551
[2]	Huang FI, Chen YL, Chang CN, et al. Hepatocyte growth factor activates Wnt pathway by transcriptional activation of LEF1 to facilitate tumor invasion[J]. Carcinogenesis, 2012, 33(6):1142-1148. DOI: 10.1093/carcin/bgs131. doi: 10.1093/carcin/bgs131
[3]	Skulimowski A, Durczyński A, Strzelczyk J, et al. Comparison of clinical usefulness of serum Ca125 and CA19-9 in pancreatic adenocarcinoma diagnosis: meta-analysis and systematic review of literature[J]. Biomarkers, 2021, 26(4):287-295. DOI: 10.1080/1354750X.2021.1876770. doi: 10.1080/1354750X.2021.1876770
[4]	Nusse R, Clevers H. Wnt/β-catenin signaling, disease, and emerging therapeutic modalities[J]. Cell, 2017, 169(6):985-999. DOI: 10.1016/j.cell.2017.05.016. doi: S0092-8674(17)30547-0 pmid: 28575679
[5]	Behrens J, von Kries JP, Kühl M, et al. Functional interaction of beta-catenin with the transcription factor LEF-1[J]. Nature, 1996, 382(6592):638-642. DOI: 10.1038/382638a0. doi: 10.1038/382638a0
[6]	Del Pozo Martin Y, Park D, Ramachandran A, et al. Mesenchymal cancer cell-stroma crosstalk promotes niche activation, epithelial reversion, and metastatic colonization[J]. Cell Rep, 2015, 13(11):2456-2469. DOI: 10.1016/j.celrep.2015.11.025. doi: S2211-1247(15)01325-X pmid: 26670048
[7]	McHugh KE, Stelow EB, Harrison GP, et al. The usefulness of lymphoid enhancer-binding factor 1 and androgen receptor in diagnosing solid pseudopapillary neoplasm of the pancreas on cytopathology[J]. Cancer Cytopathol, 2019, 127(11):700-707. DOI: 10.1002/cncy.22186. doi: 10.1002/cncy.22186
[8]	Kermanshahi TR, Jayachandran P, Chang DT, et al. LEF-1 is frequently expressed in colorectal carcinoma and not in other gastrointestinal tract adenocarcinomas: an immunohistochemical survey of 602 gastrointestinal tract neoplasms[J]. Appl Immunohistochem Mol Morphol, 2014, 22(10):728-734. DOI: 10.1097/PAI.0000000-000000109. doi: 10.1097/PAI.0000000-000000109
[9]	Papagerakis P, Pannone G, Shabana AH, et al. Aberrant beta-catenin and LEF1 expression may predict the clinical outcome for patients with oropharyngeal cancer[J]. Int J Immunopathol Pharmacol, 2012, 25(1):135-146. DOI: 10.1177/039463201202500116. doi: 10.1177/039463201202500116 pmid: 22507326
[10]	穆德广, 金发光, 谢永宏, 等. 淋巴增强因子-1与肺癌侵袭、转移的相关性研究[J]. 现代生物医学进展, 2013, 13(28):5460-5462. DOI: 10.13241/j.cnki.pmb.2013.28.047. doi: 10.13241/j.cnki.pmb.2013.28.047
[11]	Walther N, Ulrich A, Vockerodt M, et al. Aberrant lymphocyte enhancer-binding factor 1 expression is characteristic for sporadic Burkitt's lymphoma[J]. Am J Pathol, 2013, 182(4):1092-1098. DOI: 10.1016/j.ajpath.2012.12.013. doi: 10.1016/j.ajpath.2012.12.013 pmid: 23375451
[12]	Wang WJ, Yao Y, Jiang LL, et al. Knockdown of lymphoid enhancer factor 1 inhibits colon cancer progression in vitro and in vivo[J]. PLoS One, 2013, 8(10):e76596. DOI: 10.1371/journal.pone.0076596. doi: 10.1371/journal.pone.0076596
[13]	Wang WJ, Yao Y, Jiang LL, et al. Increased LEF1 expression and decreased Notch2 expression are strong predictors of poor outcomes in colorectal cancer patients[J]. Dis Markers, 2013, 35(5):395-405. DOI: 10.1155/2013/983981. doi: 10.1155/2013/983981
[14]	Wu W, Zhu H, Fu Y, et al. High LEF1 expression predicts adverse prognosis in chronic lymphocytic leukemia and may be targeted by ethacrynic acid[J]. Oncotarget, 2016, 7(16):21631-21643. DOI: 10.18632/oncotarget.7795. doi: 10.18632/oncotarget.7795

临床病理特征	例数	LEF-1		χ²值	P值	临床病理特征	例数	LEF-1		χ²值	P值
临床病理特征	例数	高表达	低表达	χ²值	P值	临床病理特征	例数	高表达	低表达	χ²值	P值
性别						肿瘤大小(cm)
男性	27	20	7	0.019	0.891	≤2.0	11	8	3
女性	18	13	5			2.1~4.0	22	18	4	―	0.379
年龄(岁)						>4.0	12	7	5
≤60	24	17	7	0.164	0.685	肿瘤浸润情况
>60	21	16	5			无浸润	24	16	8
BMI(kg/m²)						十二指肠黏膜层	2	2	0
<18.5	2	2	0			十二指肠黏膜下层	4	2	2	―	0.440
18.5~23.9	19	14	5	―	>0.999	十二指肠肌层	5	4	1
≥24.0	24	17	7			十二指肠浆膜层	10	9	1
糖尿病						局部淋巴结转移
无	37	29	8	―	0.181	无	18	10	8	―	0.041
有	8	4	4			有	27	23	4
术前总胆红素(μmol/L)						TNM分期
≤17.1	13	11	2	―	0.460	Ⅰa	2	1	1
>17.1	32	22	10			Ⅰb	14	9	5
术前直接胆红素(μmol/L)						Ⅱa	11	7	4	―	0.301
≤6.8	16	13	3	―	0.491	Ⅱb	17	15	2
>6.8	29	20	9			Ⅲ	1	1	0
术前CA19-9(U/ml)						肿瘤分化程度
≤40	12	4	8	―	<0.001	高分化	16	9	7
>40	33	29	4			中分化	14	13	1	―	0.089
术前CA125(U/ml)						低分化	15	11	4
≤35	37	26	11	―	0.419
>35	8	7	1

临床病理特征	HR值	95% CI	P值
性别	1.585	0.849~2.958	0.148
年龄	1.962	1.043~3.692	0.037
BMI	0.819	0.475~1.412	0.472
有无糖尿病	1.989	0.880~4.496	0.099
术前总胆红素	0.580	0.295~1.140	0.114
术前直接胆红素	0.615	0.321~1.176	0.142
CA19-9	2.667	1.258~5.656	0.011
CA125	0.801	0.369~1.739	0.575
原发肿瘤大小	1.242	0.855~1.804	0.254
原发肿瘤浸润情况	0.909	0.764~1.081	0.279
局部淋巴结转移	1.150	0.625~2.114	0.654
肿瘤分期	1.123	0.841~1.501	0.432
肿瘤分化	1.124	0.793~1.593	0.513
LEF-1	2.253	1.097~4.630	0.027

[1]	钱晓涛, 石子宜, 胡格, 吴晓维. Ⅲ~ⅣA期食管鳞状细胞癌放化疗后行巩固化疗的疗效：一项真实世界临床研究[J]. 国际肿瘤学杂志, 2024, 51(6): 326-331.
[2]	杨蜜, 别俊, 张加勇, 邓佳秀, 唐组阁, 卢俊. 局部晚期可切除食管癌新辅助治疗疗效及预后分析[J]. 国际肿瘤学杂志, 2024, 51(6): 332-337.
[3]	范志鹏, 余静, 胡静, 廖正凯, 徐禹, 欧阳雯, 谢丛华. 炎症标志物的变化趋势对一线接受免疫联合化疗的晚期非小细胞肺癌患者预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(5): 257-266.
[4]	杨琳, 路宁, 温华, 张明鑫, 朱琳. 炎症负荷指数与胃癌临床关系研究[J]. 国际肿瘤学杂志, 2024, 51(5): 274-279.
[5]	张洁, 范玲, 李杰, 温华, 苏媛媛, 路宁, 张明鑫. 原发性胰腺淋巴瘤1例并文献复习[J]. 国际肿瘤学杂志, 2024, 51(5): 316-320.
[6]	刘萍萍, 何学芳, 张翼, 杨旭, 张珊珊, 季一飞. 原发性脑胶质瘤患者术后复发危险因素及预测模型构建[J]. 国际肿瘤学杂志, 2024, 51(4): 193-197.
[7]	万芳, 杨钢, 李睿, 万启晶. 食管癌患者血清miR-497、miR-383水平及临床意义[J]. 国际肿瘤学杂志, 2024, 51(4): 204-209.
[8]	姚益新, 沈煜霖. 血清SOCS3、TXNIP水平对肝细胞癌TACE治疗预后的预测价值[J]. 国际肿瘤学杂志, 2024, 51(4): 217-222.
[9]	孙维蔚, 姚学敏, 王鹏健, 王静, 贾敬好. 基于血液学指标探讨免疫治疗晚期非小细胞肺癌预后因素及列线图构建[J]. 国际肿瘤学杂志, 2024, 51(3): 143-150.
[10]	刘玉兰, 井海燕, 孙静, 宋伟, 沙丹. 胃癌免疫治疗疗效预测及预后标志物的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 175-180.
[11]	彭琴, 蔡玉婷, 王伟. KPNA2在肝癌中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(3): 181-185.
[12]	陈波光, 王苏贵, 张永杰. 血清胆碱酯酶与炎症标志物在ⅠA~ⅢA期乳腺癌预后中的作用[J]. 国际肿瘤学杂志, 2024, 51(2): 73-82.
[13]	金旭东, 陈忠坚, 毛伟敏. MTAP基因在恶性间皮瘤中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(2): 99-104.
[14]	黄镇, 陈永顺. 循环肿瘤DNA在肝细胞癌诊疗中的研究进展[J]. 国际肿瘤学杂志, 2024, 51(1): 59-64.
[15]	王潇, 李盈, 罗玉杰, 晋舒. 基于列线图模型探讨血清学指标对鼻咽癌预后的判断价值[J]. 国际肿瘤学杂志, 2023, 50(8): 463-469.